Skip to main content

Ipsogen, Sysmex Reach Distribution Deal

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics firm Ipsogen today announced a distribution deal with Sysmex covering Japan.

Under the deal, Sysmex, based in Kobe, Japan, will distribute certain Ipsogen blood cancer products in Japan. Sysmex also will be responsible for the regulatory submission of Ipsogen products directed at the diagnosis and monitoring of BCR-ABL and JAK2 to Japanese health authorities. Sysmex has the exclusive rights to sell these products in Japan.

Financial and other terms were not disclosed.

"We believe the combination of Sysmex's marketing reach and expertise in hematology and the unique Ipsogen products offering represent an excellent opportunity for Japanese patients to access our standardized solutions for the personalized treatment of blood cancer," Vincent Fert, CEO of Ipsogen, said in a statement.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.